Papers
4
Total Citations
125
H-Index
4
About
Ranee Mehra is a leading oncologist whose research has fundamentally reshaped the treatment landscape for HPV-related oropharyngeal cancer. Her primary focus is on treatment de-escalation—reducing the intensity of therapy to minimize long-term toxicities without compromising cure rates. Dr. Mehra’s most monumental contribution is her leadership in the landmark ECOG-ACRIN E3311 trial, which demonstrated that patients with intermediate-risk p16+ oropharynx cancer can safely receive a lower dose of radiation (50 Gy) after transoral robotic surgery, achieving excellent two-year progression-free survival. This practice-changing study, cited over 100 times, has established a new standard for de-intensified, function-preserving care. She has also pioneered the rigorous surgeon credentialing and quality assurance processes essential for multi-institutional surgical trials, ensuring reproducibility and safety. Additionally, Dr. Mehra is investigating the SAVER protocol, which explores selectively avoiding radiation to low-risk nodal volumes in the contralateral neck. Through her work, she has provided robust evidence that surgery is a powerful tool for personalizing therapy, enabling thousands of patients to avoid the debilitating side effects of high-dose chemoradiation while maintaining outstanding oncologic outcomes.
Research Focus
Key Achievements
Top Papers
- 1
- 2The role of surgery and deescalation for HPV‐related oropharyngeal cancer10 citations · 2024
- 3
- 4